Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Analysis of Vancomycin-Resistant Enterococci in Hemato-Oncological Patients

K. Hricová, T. Štosová, P. Kučová, K. Fišerová, J. Bardoň, M. Kolář,

. 2020 ; 9 (11) : . [pub] 20201107

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001802

Grantová podpora
NV18-05-00340 Agentura Pro Zdravotnický Výzkum České Republiky

Enterococci are important bacterial pathogens, and their significance is even greater in the case of vancomycin-resistant enterococci (VRE). The study analyzed the presence of VRE in the gastrointestinal tract (GIT) of hemato-oncological patients. Active screening using selective agars yielded VRE for phenotypic and genotypic analyses. Isolated strains were identified with MALDI-TOF MS, (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) their susceptibility to antibiotics was tested, and resistance genes (vanA, vanB, vanC-1, vanC2-C3) and genes encoding virulence factors (asa1, gelE, cylA, esp, hyl) were detected. Pulsed-field gel electrophoresis was used to assess the relationship of the isolated strains. Over a period of three years, 103 VanA-type VRE were identified in 1405 hemato-oncological patients. The most frequently detected virulence factor was extracellular surface protein (84%), followed by hyaluronidase (40%). Unique restriction profiles were observed in 33% of strains; clonality was detected in 67% of isolates. The study found that 7% of hemato-oncological patients carried VRE in their GIT. In all cases, the species identified was Enterococcus faecium. No clone persisted for the entire 3-year study period. However, genetically different clusters were observed for shorter periods of time, no longer than eight months, with identical VRE spreading among patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001802
003      
CZ-PrNML
005      
20210126092745.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antibiotics9110785 $2 doi
035    __
$a (PubMed)33171728
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hricová, Kristýna $u Department of Microbiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, 77900 Olomouc, Czech Republic.
245    10
$a Analysis of Vancomycin-Resistant Enterococci in Hemato-Oncological Patients. / $c K. Hricová, T. Štosová, P. Kučová, K. Fišerová, J. Bardoň, M. Kolář,
520    9_
$a Enterococci are important bacterial pathogens, and their significance is even greater in the case of vancomycin-resistant enterococci (VRE). The study analyzed the presence of VRE in the gastrointestinal tract (GIT) of hemato-oncological patients. Active screening using selective agars yielded VRE for phenotypic and genotypic analyses. Isolated strains were identified with MALDI-TOF MS, (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) their susceptibility to antibiotics was tested, and resistance genes (vanA, vanB, vanC-1, vanC2-C3) and genes encoding virulence factors (asa1, gelE, cylA, esp, hyl) were detected. Pulsed-field gel electrophoresis was used to assess the relationship of the isolated strains. Over a period of three years, 103 VanA-type VRE were identified in 1405 hemato-oncological patients. The most frequently detected virulence factor was extracellular surface protein (84%), followed by hyaluronidase (40%). Unique restriction profiles were observed in 33% of strains; clonality was detected in 67% of isolates. The study found that 7% of hemato-oncological patients carried VRE in their GIT. In all cases, the species identified was Enterococcus faecium. No clone persisted for the entire 3-year study period. However, genetically different clusters were observed for shorter periods of time, no longer than eight months, with identical VRE spreading among patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Štosová, Taťána $u Department of Microbiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Kučová, Pavla $u Department of Microbiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Fišerová, Kateřina $u Department of Microbiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Bardoň, Jan $u Department of Microbiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Kolář, Milan $u Department of Microbiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, 77900 Olomouc, Czech Republic.
773    0_
$w MED00195446 $t Antibiotics (Basel, Switzerland) $x 2079-6382 $g Roč. 9, č. 11 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33171728 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092740 $b ABA008
999    __
$a ind $b bmc $g 1614020 $s 1122086
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 11 $e 20201107 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics $x MED00195446
GRA    __
$a NV18-05-00340 $p Agentura Pro Zdravotnický Výzkum České Republiky
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...